Concord Medical Services Holdings (Concord Medical Services Holdings) COGS-to-Revenue : 1.15 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Concord Medical Services Holdings COGS-to-Revenue?

Concord Medical Services Holdings's Cost of Goods Sold for the six months ended in Dec. 2023 was $40.91 Mil. Its Revenue for the six months ended in Dec. 2023 was $35.42 Mil.

Concord Medical Services Holdings's COGS to Revenue for the six months ended in Dec. 2023 was 1.15.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Concord Medical Services Holdings's Gross Margin % for the six months ended in Dec. 2023 was -15.49%.

Concord Medical Services Holdings COGS-to-Revenue Historical Data

The historical data trend for Concord Medical Services Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Medical Services Holdings COGS-to-Revenue Chart

Concord Medical Services Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

1.08

0.94

1.12

1.32

1.14

Concord Medical Services Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															1.20	1.62	1.19	1.13	1.15

Concord Medical Services Holdings COGS-to-Revenue Calculation

Concord Medical Services Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	85.993	/	75.264
	=	1.14

Concord Medical Services Holdings's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	40.906	/	35.418
	=	1.15

Concord Medical Services Holdings (NYSE:CCM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Concord Medical Services Holdings's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	40.906 / 35.418
	=	-15.49 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Concord Medical Services Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Concord Medical Services Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Medical Services Holdings (Concord Medical Services Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Concord Medical Services Holdings Ltd (NYSE:CCM) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room 2701-05 , 36 North Third Ring Road, Tower A, Global Trade Center, Dongcheng District, Beijing, CHN, 100013

Website

https://ir.ccm.cn

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers and diagnostic imaging centers and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.